1
Clinical Trials associated with mRNA-CR-04(GSK) / Active, not recruitingPhase 1 Exploratory, First Time in Human (FTIH), Observer-blind, Randomized, Controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of Various Doses of GlaxoSmithKline Biologicals SA's (GSK) Investigational Omicron Variant S Glycoprotein (mRNA-CR-04) Vaccine When Administered Intramuscularly in Healthy Adults 18 to 49 Years of Age
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
100 Clinical Results associated with mRNA-CR-04(GSK)
100 Translational Medicine associated with mRNA-CR-04(GSK)
100 Patents (Medical) associated with mRNA-CR-04(GSK)
100 Deals associated with mRNA-CR-04(GSK)